Highlights
- Sitagliptin is as effective as glipizide at lowering blood sugar levels in patients with type 2 diabetes and chronic kidney disease.
- Sitagliptin is less likely than glipizide to cause dangerously low blood sugar levels.
- Patients on sitagliptin tend to lose weight, while those on glipizide gain weight.
Some blood-sugar-lowering drugs have caused kidney problems in patients with type 2 diabetes, so physicians are especially cautious when prescribing these agents to diabetics who also have chronic kidney disease (CKD).
Previous research indicates that the diabetes drugs sitagliptin and glipizide may not cause considerable kidney damage. New clinical trial results presented during the American Society of Nephrology's Annual Kidney Week compared the two drugs.
Sitagliptin and glipizide act on different targets but generate the same result—they boost the effects of insulin, which lowers blood sugar levels.
Juan Arjona Ferreira, MD, (MSD Corp.) and his colleagues conducted a 54-week study to compare the efficacy and safety of sitagliptin and glipizide in patients with type 2 diabetes and moderate or severe CKD who were not on dialysis. The researchers randomized 426 patients to receive sitagliptin or glipizide.
Among the major findings at the end of the study:
- Blood glucose levels dropped to a similar extent in patients in both groups.
- Patients receiving sitagliptin were less likely to experience hypoglycemia—or dangerously low blood sugar levels—than patients receiving glipizide (6.2% vs 17.0%).
- Patients who took sitagliptin tended to lose a small amount of weight, while most patients who took glipizide experienced a slight weight gain.
Study authors for "Efficacy and Safety of Sitagliptin vs. Glipizide in Patients with Type 2 Diabetes and Moderate to Severe Chronic Renal Insufficiency" (abstract LB-PO3166) include Juan Arjona Ferreira, MD, Michel Marre, MD, PhD, George Bakris, MD, and Ton Rabelink, MD, PhD.
Disclosures: Juan Arjona Ferreira is employed by and has ownership interest in Merck Sharp & Dohme, Corp. Michel Marre receives honoraria from is a scientific advisor for or has other relationships with Abbott, Eli Lilly, MSD, Novo Nordisk, Sanofi Aventis, and Servier. George Bakris has consultancy agreements with CVRx, Relapsya, Johnson & Johnson, Medtronic, Merck, Abbott, Takeda, and Reata; and receives research funding from Novartis, Forest, and Takeda. Ton Rabelink receives speaker fees from Daiichi Sankyo.
ASN Kidney Week 2011, the largest nephrology meeting of its kind, will provide a forum for 13,000 professionals to discuss the latest findings in renal research and engage in educational sessions related to advances in the care of patients with kidney and related disorders. Kidney Week 2011 will take place November 8 – November 13 at the Pennsylvania Convention Center in Philadelphia, PA.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 12,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.